Racial Disparities in Diabetes Mellitus Prevalence in Prostate Cancer Patients on Androgen Deprivation Therapy

Authors

Sameh Gomaa, Thomas Jefferson UniversityFollow
William Kelly, DO, Thomas Jefferson UniversityFollow
Grace Lu-Yao, PhD, Thomas Jefferson UniversityFollow
Edith Mitchell, MD, Thomas Jefferson UniversityFollow
Tingting Zhan, PhD, Thomas Jefferson UniversityFollow
Kuang-Yi Wen, PhD, Thomas Jefferson UniversityFollow

Files

Description

Intro/Background

• Androgen deprivation therapy (ADT) is successfully used in patients with advanced prostate cancer.
• ADT has show to prolong survival.
• The use of ADT is associated with many side effects, most notably an increase in diabetes incidence for patients on ADT.
• African American men have higher prevalence and mortality rates from prostate cancer than White men.
• It is unclear how prostate cancer treatment such as ADT affects these disparities.
• This study examines racial differences in the prevalence of diabetes mellitus in prostate cancer patients based on their ADT status in the US.

Publication Date

9-18-2022

Keywords

medical oncology, disparities, prostate cancer, diabetes mellitus

Disciplines

Medicine and Health Sciences | Oncology

Comments

Presented at the 2022 AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.

Recommended Citation

Gomaa, Sameh; Kelly, DO, William; Lu-Yao, PhD, Grace; Mitchell, MD, Edith; Zhan, PhD, Tingting; and Wen, PhD, Kuang-Yi, "Racial Disparities in Diabetes Mellitus Prevalence in Prostate Cancer Patients on Androgen Deprivation Therapy" (2022). Department of Medical Oncology Posters. 16.
https://jdc.jefferson.edu/medoncposters/16